Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (111-120 of 250) with videos related to

Pageof 25
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 24, 2015
Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancerJi Hyun Park, Min-Hee Ryu, Hwa Jung Kim, et al.
Cancer Immunology Research|April 9, 2020
CD226<sup>hi</sup>CD8<sup>+</sup> T Cells Are a Prerequisite for Anti-TIGIT ImmunotherapyHyung-Seung Jin, Minkyung Ko, Da-Som Choi, et al.
In Vivo (Athens, Greece)|March 1, 2020
Rivaroxaban <i>Versus</i> Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary CancerJwa Hoon Kim, Seyoung Seo, Kyu-Pyo Kim, et al.
Oncotarget|November 5, 2017
Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitorsYoung-Soon Na, Min-Hee Ryu, Changhoon Yoo, et al.
Cancer Research and Treatment|April 12, 2022
Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract CancerJihoon Kang, Ji-Young Lee, Sunmin Lee, et al.
The Lancet. Oncology|October 17, 2021
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b studyChanghoon Yoo, Kyu-Pyo Kim, Jae Ho Jeong, et al.
Alimentary Pharmacology & Therapeutics|January 28, 2025
Risk of Variceal Bleeding in Patients Receiving Atezolizumab-Bevacizumab Treatment for Hepatocellular CarcinomaKanghee Park, Hye Won Lee, Euichang Kim, et al.
Journal of Digestive Diseases|July 4, 2017
Clinical outcomes of patients with resectable pancreatic acinar cell carcinomaSeyoung Seo, Changhoon Yoo, Kyu-Poy Kim, et al.
Journal of Hepatology|March 27, 2025
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trialsChanghoon Yoo, Anna Saborowski, Jaewon Hyung, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 18, 2021
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinomaJaekyung Cheon, Changhoon Yoo, Jung Yong Hong, et al.
Pageof 25

Showing results (111-120 of 250) with videos related to

Sort By:
Pageof 25
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 24, 2015
Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancerJi Hyun Park, Min-Hee Ryu, Hwa Jung Kim, et al.
Cancer Immunology Research|April 9, 2020
CD226<sup>hi</sup>CD8<sup>+</sup> T Cells Are a Prerequisite for Anti-TIGIT ImmunotherapyHyung-Seung Jin, Minkyung Ko, Da-Som Choi, et al.
In Vivo (Athens, Greece)|March 1, 2020
Rivaroxaban <i>Versus</i> Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary CancerJwa Hoon Kim, Seyoung Seo, Kyu-Pyo Kim, et al.
Oncotarget|November 5, 2017
Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitorsYoung-Soon Na, Min-Hee Ryu, Changhoon Yoo, et al.
Cancer Research and Treatment|April 12, 2022
Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract CancerJihoon Kang, Ji-Young Lee, Sunmin Lee, et al.
The Lancet. Oncology|October 17, 2021
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b studyChanghoon Yoo, Kyu-Pyo Kim, Jae Ho Jeong, et al.
Alimentary Pharmacology & Therapeutics|January 28, 2025
Risk of Variceal Bleeding in Patients Receiving Atezolizumab-Bevacizumab Treatment for Hepatocellular CarcinomaKanghee Park, Hye Won Lee, Euichang Kim, et al.
Journal of Digestive Diseases|July 4, 2017
Clinical outcomes of patients with resectable pancreatic acinar cell carcinomaSeyoung Seo, Changhoon Yoo, Kyu-Poy Kim, et al.
Journal of Hepatology|March 27, 2025
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trialsChanghoon Yoo, Anna Saborowski, Jaewon Hyung, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 18, 2021
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinomaJaekyung Cheon, Changhoon Yoo, Jung Yong Hong, et al.
Pageof 25